742716
Last Update Posted: 2014-11-06
Recruiting has ended
All Genders accepted | 18 Years-80 Years |
41 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
This study will investigate the levels of CTA018 in the body over time (pharmacokinetics, PK) in patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT), undergoing regular hemodialysis. This study will also investigate the safety and effects of different strengths of CTA018, on parathyroid hormone (PTH) levels.
Eligibility
Relevant conditions:
Chronic Kidney Disease
Secondary Hyperparathyroidism
Chronic Renal Insufficiency
Chronic Renal Failure
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov